MedTrace Logo

Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis

NCT06174402 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2026-01-08

No results posted yet for this study

Summary

The main objectives of the study were to assess the effects of fenofibrate on serum alkaline phosphatase, as a composite endpoint and on safety in participants with primary biliary cholangitis (PBC)

Conditions

Interventions

DRUG

Fenofibrate

Fenofibrate 200 mg/day

DRUG

Placebo

1 tablet/ day

DRUG

UDCA

UDCA 13-15mg/kg/day

Sponsors & Collaborators

  • Han Ying

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-21
Primary Completion
2026-07-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06174402 on ClinicalTrials.gov